ArticleJournal of neuroinflammation2026
CMV titer associations with cognition and the plasma proteome implicate FLT1 and neurovascular mechanisms as potential moderators.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Immune processes play complex roles in Alzheimer’s disease and related dementias (ADRD), but it remains unclear whether host defenses against common microbes also contribute to ADRD, and what underlying mechanisms may account for these relationships. Using antibody and plasma proteomic data from the Monongahela-Youghiogheny Healthy Aging Team study (n = 1,003; mean age = 78.0 yrs; follow up 7.6 yrs), the present study detected accelerated decline across a variety of cognitive domains and altered plasma abundance of FLT1 (also known as Vascular Endothelial Growth Factor Receptor 1) among participants with elevated cytomegalovirus (CMV) titers. After analyses in the Baltimore Longitudinal Study of Aging (n = 323) and the UK Biobank (n = 956) revealed CMV titer associations with higher cross-sectional cognition and greater cognitive decline were moderated by plasma FLT1 abundance, we leveraged two-sample Mendelian Randomization to uncover causal roles for host immune responses to CMV, including limiting brain amyloidosis. Using multi-cohort proteomic signatures of CMV antibody levels and plasma FLT1, bioinformatic analyses suggested that host immune responses to CMV may impact neurologic health through alterations in lymphocytic immunoregulatory cascades, with circulating FLT1 abundance capturing the extent to which these effects may be transmitted across the blood–brain-barrier. In addition to detecting pleiotropic associations of CMV titers with neurocognitive outcomes, our findings highlight FLT1 as an important molecular moderator of these effects, and extend our understanding of the biological basis by which host immune responses to common microbes may contribute to ADRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.